Dato-DXd
Datopotamab deruxtecan plus pembrolizumab with or without platinum-based chemotherapy for advanced or metastatic NSCLC: The phase 1b TROPION-Lung02 trial
This site is for U.S. Healthcare Professionals only.
Publications
This section includes selected Daiichi Sankyo-sponsored publications.
The content contained is subject to congress/journal copyright permissions. No further reproduction is permitted without permission of the copyright owner.
Information about pipeline compounds or investigational uses of compounds does not imply FDA approval for these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the pipeline compounds or investigational uses will receive FDA approval. Daiichi Sankyo does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling.
T-DXd
Breast Cancer
DESTINY-Breast08: A phase 1b study of trastuzumab deruxtecan in combination with other anticancer therapies in patients with HER2-low metastatic breast cancer
Jhaveri K, Loi S, Hamilton E, et al.
Clin Cancer Res. 2026 Mar 16;32(6):1046-1058. doi: 10.1158/1078-0432.CCR-25-0874.
T-DXd
Gastric Cancer
Impact of prior immune checkpoint inhibitor on trastuzumab deruxtecan in HER2-positive advanced gastric cancer: Exploratory analysis of the EN-DEAVOR study
Narita Y, Kawakami H, Nakanishi K, et al.
Jpn J Clin Oncol. 2026 Mar 6:hyaf216. doi: 10.1093/jjco/hyaf216.
T-DXd
Breast Cancer
Capivasertib combines with trastuzumab deruxtecan to enhance anti-tumour activity in HER2-positive and HER2-low tumours
Bashi AC, Proia TA, Lawson M, wt al.
Mol Cancer Ther. 2026 Mar 6. doi: 10.1158/1535-7163.MCT-25-0875.
Dato-DXd
Lung Cancer
Osimertinib plus datopotamab deruxtecan in patients with EGFR-mutated advanced NSCLC post-progression on first-line osimertinib: ORCHARD
Riess JW, Yu HA, Le X, et al.
Ann Oncol. 2026 Mar 2:S0923-7534(26)00070-0. doi: 10.1016/j.annonc.2026.02.014.
Quizartinib
Hematology
Patient-reported outcomes in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia receiving standard chemotherapy plus quizartinib or placebo (QuANTUM-First): A global, randomised, placebo-controlled, phase 3 trial
Olíva EN, Cottone F, Unni S, et al.
Lancet Haematol. 2026 Mar;13(3):e169-e180. doi: 10.1016/S2352-3026(25)00361-8.
T-DXd
Breast Cancer
Trastuzumab deruxtecan in hormone receptor-positive, HER2-low/-ultralow metastatic breast cancer (DESTINY-Breast06): Outcome analyses by time to progression on prior first-line endocrine therapy with CDK4/6 inhibitor and baseline burden of disease
Curigliano G, Hu X, Dent R, et al.
Ann Oncol. 2026 Mar 2:S0923-7534(26)00071-2. doi: 10.1016/j.annonc.2026.02.015.
Quizartinib
Hematology
Post-marketing surveillance of quizartinib for relapsed or refractory FLT3-ITD-positive acute myeloid leukemia in Japan
Miyazaki Y, Matsumura I, Arita T, Fukuda R, Yamanaka M.
Int J Hematol. 2026 Feb 26. doi: 10.1007/s12185-026-04181-7.
Edoxaban
Cardiovascular - AF
Ischemic and bleeding events after early initiation of direct oral anticoagulants for acute intracranial hemorrhage with non-valvular atrial fibrillation - A multicenter prospective registry.
Koga M, Toyoda K, Iguchi Y, et al.
Circ J. 2026 Feb 25. doi: 10.1253/circj.CJ-25-0791.
HER3-DXd
Other/Multi
The impact of HER3 dynamics altered by HER3-DXd alone and in combination with driver oncogene inhibitors on HER3-DXd efficacy
Komatsu N, Sato S, Nakamura R, et al.
Int J Mol Sci. 2026 Feb 17;27(4):1930. doi: 10.3390/ijms27041930.
DataSource by Daiichi Sankyo website provides U.S.
healthcare professionals with high quality, fair balanced, evidence-based medical information.
The information provided is for education purposes only and is not intended as medical advice.
Please choose an option below